2022 年全球肺癌负担及到 2050 年的预测：来自 GLOBOCAN 的发病率和死亡率估算。

IF 2.4 3区医学 Q3 ONCOLOGY

Cancer Epidemiology Pub Date : 2024-11-13 DOI:10.1016/j.canep.2024.102693

Jialin Zhou , Ying Xu , Jianmin Liu , Lili Feng , Jinming Yu , Dawei Chen

{"title":"2022 年全球肺癌负担及到 2050 年的预测：来自 GLOBOCAN 的发病率和死亡率估算。","authors":"Jialin Zhou , Ying Xu , Jianmin Liu , Lili Feng , Jinming Yu , Dawei Chen","doi":"10.1016/j.canep.2024.102693","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Lung cancer continues to pose a serious global public health challenge. Timely evidence on the global epidemiological profile of the disease is crucial to facilitate the implementation to lung cancer control efforts. This study provides updated global estimates for lung cancer incidence and mortality in 2022, along with projections for new cases and deaths up to 2050.</div></div><div><h3>Methods</h3><div>In the population-based study, we extracted data about lung cancer new cases and deaths from GLOBOCAN 2022 database across 185 countries or territories. We analyzed age-standardized rates by sex, country, region, and human development index (HDI). Projected new cases and deaths for 2050 were estimated using global demographic projections.</div></div><div><h3>Results</h3><div>In 2022, lung cancer stood as the most frequently diagnosed cancer and the primary cause of cancer-related deaths on a global scale with approximately 2.48 million new cases and 1.8 million deaths, respectively. The incidence and mortality rates of lung cancer exhibited disparities in sex and world regions. Furthermore, incidence and mortality rates increasing as HDI increased. If the incidence and mortality rates remain stable as in 2022, the burden of lung cancer is projected to increase to 4·62 million new cases and 3·55 million deaths by 2050.</div></div><div><h3>Conclusions</h3><div>Lung cancer is the predominant form of cancer and the foremost contributor to cancer-related mortality in 2022 with notable geographical, sex, and socioeconomic disparities.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"93 ","pages":"Article 102693"},"PeriodicalIF":2.4000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN\",\"authors\":\"Jialin Zhou , Ying Xu , Jianmin Liu , Lili Feng , Jinming Yu , Dawei Chen\",\"doi\":\"10.1016/j.canep.2024.102693\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Lung cancer continues to pose a serious global public health challenge. Timely evidence on the global epidemiological profile of the disease is crucial to facilitate the implementation to lung cancer control efforts. This study provides updated global estimates for lung cancer incidence and mortality in 2022, along with projections for new cases and deaths up to 2050.</div></div><div><h3>Methods</h3><div>In the population-based study, we extracted data about lung cancer new cases and deaths from GLOBOCAN 2022 database across 185 countries or territories. We analyzed age-standardized rates by sex, country, region, and human development index (HDI). Projected new cases and deaths for 2050 were estimated using global demographic projections.</div></div><div><h3>Results</h3><div>In 2022, lung cancer stood as the most frequently diagnosed cancer and the primary cause of cancer-related deaths on a global scale with approximately 2.48 million new cases and 1.8 million deaths, respectively. The incidence and mortality rates of lung cancer exhibited disparities in sex and world regions. Furthermore, incidence and mortality rates increasing as HDI increased. If the incidence and mortality rates remain stable as in 2022, the burden of lung cancer is projected to increase to 4·62 million new cases and 3·55 million deaths by 2050.</div></div><div><h3>Conclusions</h3><div>Lung cancer is the predominant form of cancer and the foremost contributor to cancer-related mortality in 2022 with notable geographical, sex, and socioeconomic disparities.</div></div>\",\"PeriodicalId\":56322,\"journal\":{\"name\":\"Cancer Epidemiology\",\"volume\":\"93 \",\"pages\":\"Article 102693\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Epidemiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1877782124001723\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Epidemiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877782124001723","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：肺癌继续对全球公共卫生构成严重挑战。及时提供有关该疾病全球流行病学概况的证据对于促进肺癌控制工作的实施至关重要。本研究提供了 2022 年全球肺癌发病率和死亡率的最新估计值，以及到 2050 年新增病例和死亡人数的预测值：在这项基于人群的研究中，我们从 GLOBOCAN 2022 数据库中提取了 185 个国家或地区的肺癌新发病例和死亡病例数据。我们按性别、国家、地区和人类发展指数（HDI）分析了年龄标准化比率。我们还利用全球人口预测估算了 2050 年的新增病例和死亡人数：结果：2022 年，肺癌是全球最常见的癌症，也是癌症相关死亡的主要原因，新增病例和死亡人数分别约为 248 万和 180 万。肺癌的发病率和死亡率在性别和世界地区之间存在差异。此外，发病率和死亡率随着人类发展指数的增加而增加。如果发病率和死亡率与 2022 年保持稳定，预计到 2050 年，肺癌的负担将增加到 4-62 万新发病例和 3-55 万死亡病例：结论：肺癌是癌症的主要形式，也是 2022 年癌症相关死亡率的首要因素，但存在明显的地域、性别和社会经济差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN

Background

Lung cancer continues to pose a serious global public health challenge. Timely evidence on the global epidemiological profile of the disease is crucial to facilitate the implementation to lung cancer control efforts. This study provides updated global estimates for lung cancer incidence and mortality in 2022, along with projections for new cases and deaths up to 2050.

Methods

In the population-based study, we extracted data about lung cancer new cases and deaths from GLOBOCAN 2022 database across 185 countries or territories. We analyzed age-standardized rates by sex, country, region, and human development index (HDI). Projected new cases and deaths for 2050 were estimated using global demographic projections.

Results

In 2022, lung cancer stood as the most frequently diagnosed cancer and the primary cause of cancer-related deaths on a global scale with approximately 2.48 million new cases and 1.8 million deaths, respectively. The incidence and mortality rates of lung cancer exhibited disparities in sex and world regions. Furthermore, incidence and mortality rates increasing as HDI increased. If the incidence and mortality rates remain stable as in 2022, the burden of lung cancer is projected to increase to 4·62 million new cases and 3·55 million deaths by 2050.

Conclusions

Lung cancer is the predominant form of cancer and the foremost contributor to cancer-related mortality in 2022 with notable geographical, sex, and socioeconomic disparities.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Epidemiology 医学-肿瘤学

CiteScore

4.50

自引率

3.80%

发文量

200

审稿时长

39 days

期刊介绍： Cancer Epidemiology is dedicated to increasing understanding about cancer causes, prevention and control. The scope of the journal embraces all aspects of cancer epidemiology including: • Descriptive epidemiology • Studies of risk factors for disease initiation, development and prognosis • Screening and early detection • Prevention and control • Methodological issues The journal publishes original research articles (full length and short reports), systematic reviews and meta-analyses, editorials, commentaries and letters to the editor commenting on previously published research.